One intriguing aspect of our findings is that inactivation of Apelin not only reduces tumor growth and cancer neo‐angiogenesis in combination with anti‐angiogenic therapy, but results in tumor blood vessel normalization as defined by less capillary leakage, reduced tissue hypoxia, and maintained pericyte coverage. The gene discussed is APLN; the disease is cancer.